With Amgen's deal to acquire Celgen's OTEZLA, Bristol-Myers Squibb (NYSE: BMY) announced that it is increasing its previously planned $5 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE